drugset

drugset / Trial / NCT00772395

Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty

NCT00772395 ↗

Phase 4 Completed 78 enrolled Danderyd Hospital Sanofi · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Can risedronate given once weekly for 6 months prevent periprosthetic bone loss after uncemented total hip arthroplasty?

Timeline

Start: 2006-04
Primary completion: 2013-02
Completion: 2013-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Risedronate	Small molecule	35 mg	—

Indications